mbeck

Dr. Ellen Wasan receives a $745K CIHR grant to support her NMIN project

NMIN researcher Dr. Ellen Wasan and colleagues have been awarded a five-year CIHR Project Grant worth $745,876 to support and expand upon her NMIN-funded project, “Intranasal Vaccines for Pertussis and Influenza Using Novel Formulations of a Triple Adjuvant.”  The research aims to develop better vaccines—expanding the range of those who… Read More »Dr. Ellen Wasan receives a $745K CIHR grant to support her NMIN project

NMIN researchers discuss gene therapies for skin disease

NMIN researcher Dr. Sarah Hedtrich, her team including NanoCore`s Operational Lead Dr. Dominik Witzigmann, discuss the status of gene therapies as tools for treating skin disease in a review article published in Trends in Biotechnology. “In this review, we discuss current approaches, successes, and failures of cutaneous gene therapy and… Read More »NMIN researchers discuss gene therapies for skin disease

NMIN researchers discover dose threshold for nanoparticle tumour delivery

NMIN researchers and colleagues have discovered a nanoparticle threshold dose that improves nanoparticle delivery and therapy for solid tumours. Published in Nature Materials, the study emerged from Dr. Warren Chan‘s Integrated Nanotechnology & Biomedical Sciences Laboratory at the University of Toronto, with NMIN researchers Drs. Chan and Gang Zheng as… Read More »NMIN researchers discover dose threshold for nanoparticle tumour delivery

NMIN-Mitacs Intern developing novel cannabinoid delivery platforms

The NanoMedicines Innovation Network (NMIN) is pleased to announce the third recipient of an NMIN-Mitacs Internship. In an internship of one year’s duration, Dr. Farahnaz Fathordoobady, NMIN HQP and Postdoctoral Fellow at the University of British Columbia (UBC), will collaborate with Ascension Sciences Inc. (ASI) to develop a novel oral… Read More »NMIN-Mitacs Intern developing novel cannabinoid delivery platforms

Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.

The NanoMedicines Innovation Network (NMIN) is pleased to announce the inaugural recipients of NMIN-Mitacs Internships:  Drs. Kent Chen and Brian Hsu will both work with Cuprous Pharmaceuticals Inc. (CPI) on the development of novel nanomedicines to induce anticancer immunity, using CPI’s proprietary Metaplex technology. Dr. Kent Chen Dr. Brian Hsu… Read More »Inaugural NMIN-Mitacs Internships at Cuprous Pharmaceuticals Inc.

Lipid nanoparticle technology: poised to have a revolutionary impact

In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact